1. Home » 
  2. Markets » 
  3. Laurus Labs to Hold its AGM on July 11

Laurus Labs to Hold its AGM on July 11

Laurus Labs is going to hold its AGM on July 11 to discuss key issues like Standalone Financial Statements for March 31st, 2024, Interim Dividend, and Appointment of a Director.    

by Damodharan N

Updated Jun 19, 2024

Article continues below advertisement
Laurus Labs to Hold its AGM on July 11

Laurus Labs Limited has announced that its 19th Annual General Meeting (AGM) will be conducted via video conference on July 11, 2024, at 3:00 PM IST. The AGM aims to address key agenda items including the adoption of audited financial statements for the fiscal year ending March 31, 2024, and the ratification of interim dividends already paid out.

Additionally, shareholders will vote on the appointment of directors and the remuneration of cost auditors for the financial year 2024-25. The meeting underscores Laurus Labs' commitment to transparency and governance in its operations.

Ordinary Business:

  1. Adoption of audited Standalone Financial Statements for the year ended March 31, 2024.
  2. Adoption of audited Consolidated Financial Statements for the year ended March 31, 2024.
  3. Ratification of interim dividend on equity shares for the financial year 2023-24.
  4. Ratification of 2nd interim dividend on equity shares for the financial year 2023-24.
  5. Appointment of a Director in place of Mr. V V Ravi Kumar (DIN 01424180) who retires by rotation.

Special Business: 

  • Approval of remuneration payable to Cost Auditors for the financial year ending 2024-25. 
  • Appointment of Mr. Krishna Chaitanya Chava as Director. 
  • Appointment of Ms. Soumya Chava as Director.  
  • Approval of the appointment of Mr. Krishna Chaitanya Chava (DIN 06831883) as Executive Director of the Company. 
  • Approval of the appointment of Ms. Soumya Chava (DIN 06831892) as Executive Director of the Company. 
  • Approval of the appointment of Mr. Karnam Sekar as Independent Director for a period of 5 years.

These agendas will be deliberated upon during the AGM scheduled for July 11, 2024, via video conference.

Read the full notice by clicking here.

Laurus Labs Annual Report 2023-24

Laurus Labs, a prominent pharmaceutical company, has released its Annual Report for the fiscal year 2023-24. Laurus Labs initially focused on contract research and manufacturing services (CRAMS) and quickly gained recognition in the antiretroviral (ARV) domain.

Over the years, the company expanded its expertise to become a global leader in active pharmaceutical ingredients (APIs) and integrated pharmaceutical solutions, including biotechnology.

The Annual Report highlights Laurus Labs' commitment to leveraging its core capabilities in chemistry, formulation, and custom synthesis to enhance quality and affordability in the pharmaceutical industry. The company now serves a diverse range of sectors, including pharmaceuticals, animal health, cosmetics, dietary supplements, and crop science.

Financial Highlight

Amount (in crore)

Revenue from operations

5,041

EBITDA

798

Profit after tax

161

Dividend payout ratio

19%

 

Operational Highlight

Details

Partnerships with

6

Patents granted

223

R&D spends to revenue

4.8%

Reactor volume

7,762 KL

 

ESG Highlight

Value/Number

Water recycled

284,801 KL

Energy consumed

3,469,230 GJ

Employees

6,735

Community programmes supported

25+

For more detailed information on Laurus Labs' performance and strategic initiatives in the fiscal year 2023-24, you can access the full Annual Report by clicking the link here.

Article continues below advertisement
Article continues below advertisement

Laurus Labs 

Laurus Labs, founded in 2005, has rapidly emerged as a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company's journey to prominence includes achieving leadership in critical therapeutic segments such as anti-retroviral (ARV), oncology, cardiovascular, and gastro therapeutics. 

Beyond pharmaceuticals, the company has diversified into biotechnology and biologicals through its subsidiary, Laurus Bio, investing in advanced therapies like Cell and Gene therapies. With a steadfast focus on environmental stewardship and corporate governance, Laurus Labs continues to advance healthcare solutions while fostering a culture of integrity and responsibility across its global operations.


Laurus Labs to hold its AGM on July 11 - FAQs

1. What is Laurus Labs known for?   

Laurus Labs is known for Developing APIs and intermediates, focusing on therapeutic areas like ARV, oncology, cardiovascular, and gastro therapeutics.

2. When is Laurus Labs' AGM scheduled?   

Laurus Labs' AGM will be held on July 11, 2024, via video conference at 3:00 PM IST.

3. What are the key agenda items for Laurus Labs' AGM?   

The key items include Adoption of audited financial statements, ratification of interim dividends, and appointment of directors.

4. How does Laurus Labs contribute to sustainability?   

Laurus Labs ESG programs include By recycling 284,801 KL of water, consuming 3,469,230 GJ of energy, and supporting over 25 community programs.

5. In which sectors does Laurus Labs operate?   

Laurus Labs operate in areas like Pharmaceuticals, animal health, cosmetics, dietary supplements, and crop science.

Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.